ProQR Therapeutics (PRQR) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart

PRQR Stock Forecast

ProQR Therapeutics stock forecast is as follows: an average price target of $3.63 (represents a -4.97% downside from PRQR’s last price of $3.82) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

PRQR Price Target

The average price target for ProQR Therapeutics (PRQR) is $3.63 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $2.00. This represents a potential -4.97% downside from PRQR's last price of $3.82.

PRQR Analyst Ratings

Buy

According to 5 Wall Street analysts, ProQR Therapeutics's rating consensus is 'Buy'. The analyst rating breakdown for PRQR stock is 1 'Strong Buy' (20.00%), 3 'Buy' (60.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

ProQR Therapeutics Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Mar 14, 2024	Keay Nakae	Loop Capital Markets	$2.50	$2.32	7.76%	-34.55%
Dec 30, 2022	Raymond James Raymond James	Raymond James	$5.00	$3.37	48.37%	30.89%
Dec 22, 2022	Jennifer Kim	Cantor Fitzgerald	$5.00	$2.70	85.19%	30.89%
Aug 12, 2022	Keay Nakae	Chardan Capital	$2.00	$0.81	145.40%	-47.64%

Row per page

Go to

The latest ProQR Therapeutics stock forecast, released on Mar 14, 2024 by Keay Nakae from Loop Capital Markets, set a price target of $2.50, which represents a 7.76% increase from the stock price at the time of the forecast ($2.32), and a -34.55% decrease from PRQR last price ($3.82).

ProQR Therapeutics Price Target by Period

	1M	3M	12M
# Anlaysts	-	-	1
Avg Price Target	-	-	$2.50
Last Closing Price	$3.82	$3.82	$3.82
Upside/Downside	-100.00%	-100.00%	-34.55%

In the current month, the average price target of ProQR Therapeutics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to ProQR Therapeutics's last price of $3.82. This month's average price target is down NaN% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 29, 2024	Raymond James	Outperform	Strong Buy	Upgrade
Apr 18, 2024	Citigroup	Neutral	Neutral	Hold
Nov 08, 2023	Chardan Capital	-	Buy	Upgrade
Apr 07, 2023	Citigroup	Neutral	Neutral	Hold
Mar 30, 2023	JMP Securities	Market Perform	Market Outperform	Upgrade
Dec 23, 2022	Raymond James	Outperform	Outperform	Hold
Dec 22, 2022	Cantor Fitzgerald	-	Overweight	Upgrade
Dec 22, 2022	JMP Securities	Market Perform	Market Perform	Hold
Aug 11, 2022	Raymond James	-	Outperform	Upgrade

Row per page

Go to

ProQR Therapeutics's last stock rating was published by Raymond James on Oct 29, 2024. The company Upgrade its PRQR rating from "Outperform" to "Strong Buy".

ProQR Therapeutics Financial Forecast

ProQR Therapeutics Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
Revenue	-	-	-	-	-	-	-	-	-	-	-	$655.00K	$822.00K	$956.00K	$1.02M	$1.23M	$239.00K	$872.00K	$243.00K	-	-	-	-	-	-	-	-	-
Avg Forecast	$6.27M	$8.05M	$8.10M	$8.10M	$4.94M	$11.04M	$11.44M	$2.62M	$15.84M	$4.64M	$1.22M	$1.31M	$950.82K	$841.85K	$865.20K	$802.28K	$756.63K	$234.52K	$191.67K	$452.16K	$138.19K	$99.84K	$318.31K	$417.84K	$547.67K	$863.95K	$484.01K	$627.35K
High Forecast	$6.69M	$8.59M	$8.64M	$8.64M	$5.27M	$11.78M	$11.82M	$2.72M	$31.11M	$4.95M	$1.30M	$1.40M	$1.01M	$841.85K	$865.20K	$802.28K	$756.63K	$234.52K	$191.67K	$452.16K	$138.19K	$99.84K	$318.31K	$417.84K	$547.67K	$863.95K	$484.01K	$627.35K
Low Forecast	$5.86M	$7.52M	$7.56M	$7.56M	$4.61M	$10.30M	$11.06M	$2.53M	$568.06K	$4.33M	$1.14M	$1.22M	$887.39K	$841.85K	$865.20K	$802.28K	$756.63K	$234.52K	$191.67K	$452.16K	$138.19K	$99.84K	$318.31K	$417.84K	$547.67K	$863.95K	$484.01K	$627.35K
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	1
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.50%	0.86%	1.14%	1.18%	1.54%	0.32%	3.72%	1.27%	-	-	-	-	-	-	-	-	-

ProQR Therapeutics's average Quarter revenue forecast for Jun 23 based on 2 analysts is $1.22M, with a low forecast of $1.14M, and a high forecast of $1.30M. PRQR's average Quarter revenue forecast represents a 85.95% increase compared to the company's last Quarter revenue of $655.00K (Mar 23).

ProQR Therapeutics EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	1
EBITDA	-	-	-	-	-	-	-	-	-	-	-	$-9.25M	$-11.40M	$-15.13M	$-16.39M	$-16.37M	$-17.65M	$-14.47M	$-15.09M	$-11.97M	$-12.51M	$-10.59M	$-3.57M	$-15.53M	$-17.96M	$-11.63M	$-11.07M	$-13.64M
Avg Forecast	$-3.76M	$-4.83M	$-4.86M	$-4.86M	$-2.97M	$-6.62M	$-6.86M	$-14.35M	$-9.50M	$-2.78M	$-730.78K	$-15.17M	$-11.39M	$-505.11K	$-519.12K	$-15.94M	$-453.98K	$-140.71K	$-115.00K	$-10.28M	$-82.91K	$-59.90K	$-190.98K	$-15.53M	$-328.60K	$-518.37K	$-290.41K	$-13.38M
High Forecast	$-3.51M	$-4.51M	$-4.54M	$-4.54M	$-2.77M	$-6.18M	$-6.64M	$-11.48M	$-340.83K	$-2.60M	$-682.03K	$-12.14M	$-9.11M	$-505.11K	$-519.12K	$-12.75M	$-453.98K	$-140.71K	$-115.00K	$-8.22M	$-82.91K	$-59.90K	$-190.98K	$-12.42M	$-328.60K	$-518.37K	$-290.41K	$-10.70M
Low Forecast	$-4.02M	$-5.16M	$-5.19M	$-5.19M	$-3.16M	$-7.07M	$-7.09M	$-17.22M	$-18.66M	$-2.97M	$-779.53K	$-18.20M	$-13.67M	$-505.11K	$-519.12K	$-19.13M	$-453.98K	$-140.71K	$-115.00K	$-12.33M	$-82.91K	$-59.90K	$-190.98K	$-18.63M	$-328.60K	$-518.37K	$-290.41K	$-16.05M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.61%	1.00%	29.95%	31.57%	1.03%	38.87%	102.82%	131.23%	1.16%	150.89%	176.83%	18.70%	1.00%	54.65%	22.44%	38.12%	1.02%

undefined analysts predict PRQR's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than ProQR Therapeutics's previous annual EBITDA (undefined) of $NaN.

ProQR Therapeutics Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	1
Net Income	-	-	-	-	-	-	-	-	-	-	-	$-7.99M	$-10.63M	$-24.38M	$-14.67M	$-14.45M	$-18.24M	$-15.05M	$-15.75M	$-12.61M	$-13.22M	$-13.18M	$-4.11M	$-16.05M	$-18.54M	$-12.14M	$-11.65M	$-14.16M
Avg Forecast	$-6.68M	$-4.71M	$-3.93M	$-3.54M	$-6.35M	$-8.62M	$-10.17M	$-13.71M	$1.38M	$-7.02M	$-9.06M	$-14.49M	$-11.76M	$-17.31M	$-17.48M	$-15.22M	$-18.07M	$-16.76M	$-17.34M	$-10.71M	$-19.92M	$-25.95M	$-25.65M	$-15.62M	$-29.02M	$-27.14M	$-31.34M	$-12.94M
High Forecast	$-6.10M	$-4.31M	$-3.59M	$-3.23M	$907.08K	$-7.88M	$-9.29M	$-10.96M	$1.50M	$-6.41M	$-8.28M	$-11.59M	$-9.41M	$-17.31M	$-17.48M	$-12.18M	$-18.07M	$-16.76M	$-17.34M	$-8.57M	$-19.92M	$-25.95M	$-25.65M	$-12.50M	$-29.02M	$-27.14M	$-31.34M	$-10.35M
Low Forecast	$-7.26M	$-5.12M	$-4.27M	$-3.84M	$-13.61M	$-9.37M	$-11.05M	$-16.45M	$1.26M	$-7.63M	$-9.85M	$-17.38M	$-14.12M	$-17.31M	$-17.48M	$-18.26M	$-18.07M	$-16.76M	$-17.34M	$-12.86M	$-19.92M	$-25.95M	$-25.65M	$-18.75M	$-29.02M	$-27.14M	$-31.34M	$-15.53M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.55%	0.90%	1.41%	0.84%	0.95%	1.01%	0.90%	0.91%	1.18%	0.66%	0.51%	0.16%	1.03%	0.64%	0.45%	0.37%	1.09%

ProQR Therapeutics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRQR's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

ProQR Therapeutics SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	1
SG&A	-	-	-	-	-	-	-	-	-	-	-	$4.03M	$2.97M	$5.36M	$5.41M	$4.91M	$5.32M	$4.59M	$4.12M	$3.34M	$3.51M	$2.81M	$3.45M	$3.92M	$3.92M	$2.90M	$2.88M	$3.19M
Avg Forecast	$34.65M	$44.47M	$44.74M	$44.74M	$27.30M	$60.95M	$63.16M	$14.49M	$87.44M	$25.61M	$6.72M	$7.24M	$5.25M	$4.63M	$4.76M	$4.42M	$4.17M	$1.29M	$1.06M	$2.49M	$760.79K	$549.63K	$1.75M	$2.30M	$3.02M	$4.76M	$2.66M	$3.45M
High Forecast	$36.96M	$47.44M	$47.72M	$47.72M	$29.12M	$65.02M	$65.26M	$15.02M	$171.75M	$27.32M	$7.17M	$7.72M	$5.60M	$4.63M	$4.76M	$4.42M	$4.17M	$1.29M	$1.06M	$2.49M	$760.79K	$549.63K	$1.75M	$2.30M	$3.02M	$4.76M	$2.66M	$3.45M
Low Forecast	$32.33M	$41.51M	$41.75M	$41.75M	$25.48M	$56.88M	$61.06M	$13.96M	$3.14M	$23.90M	$6.28M	$6.75M	$4.90M	$4.63M	$4.76M	$4.42M	$4.17M	$1.29M	$1.06M	$2.49M	$760.79K	$549.63K	$1.75M	$2.30M	$3.02M	$4.76M	$2.66M	$3.45M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.56%	0.57%	1.16%	1.14%	1.11%	1.28%	3.56%	3.91%	1.34%	4.62%	5.11%	1.97%	1.70%	1.30%	0.61%	1.08%	0.92%

ProQR Therapeutics's average Quarter SG&A projection for Jun 23 is $6.72M, based on 2 Wall Street analysts, with a range of $6.28M to $7.17M. The forecast indicates a 67.03% rise compared to PRQR last annual SG&A of $4.03M (Mar 23).

ProQR Therapeutics EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19
# Analysts	1	1	1	1	2	1	2	2	4	2	2	2	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	1
EPS	-	-	-	-	-	-	-	-	-	-	-	$-0.10	$0.75	$-0.34	$-0.21	$-0.20	$-0.26	$-0.22	$-0.24	$-0.25	$-0.26	$-0.26	$-0.08	$-0.32	$-0.39	$-0.31	$-0.30	$-0.36
Avg Forecast	$-0.08	$-0.06	$-0.05	$-0.04	$-0.08	$-0.11	$-0.12	$-0.11	$0.02	$-0.09	$-0.11	$-0.12	$-0.18	$-0.21	$-0.21	$-0.24	$-0.22	$-0.21	$-0.21	$-0.24	$-0.24	$-0.32	$-0.31	$-0.34	$-0.36	$-0.33	$-0.38	$-0.36
High Forecast	$-0.07	$-0.05	$-0.04	$-0.04	$0.01	$-0.10	$-0.11	$-0.10	$0.02	$-0.08	$-0.10	$-0.11	$-0.17	$-0.21	$-0.21	$-0.24	$-0.22	$-0.21	$-0.21	$-0.24	$-0.24	$-0.32	$-0.31	$-0.34	$-0.36	$-0.33	$-0.38	$-0.36
Low Forecast	$-0.09	$-0.06	$-0.05	$-0.05	$-0.17	$-0.11	$-0.14	$-0.12	$0.02	$-0.09	$-0.12	$-0.13	$-0.20	$-0.21	$-0.21	$-0.24	$-0.22	$-0.21	$-0.21	$-0.24	$-0.24	$-0.32	$-0.31	$-0.34	$-0.36	$-0.33	$-0.38	$-0.36
Surprise %	-	-	-	-	-	-	-	-	-	-	-	0.84%	-4.09%	1.60%	0.98%	0.84%	1.18%	1.07%	1.13%	1.03%	1.07%	0.82%	0.25%	0.94%	1.10%	0.93%	0.78%	0.99%

According to 2 Wall Street analysts, ProQR Therapeutics's projected average Quarter EPS for Mar 23 is $-0.12, with a low estimate of $-0.13 and a high estimate of $-0.11. This represents a -115.60% decrease compared to PRQR previous annual EPS of $0.75 (Dec 22).

ProQR Therapeutics Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
SPRO	Spero Therapeutics	$1.18	$10.00	747.46%	Buy
CTMX	CytomX Therapeutics	$0.91	$5.73	529.67%	Buy
TIL	Instil Bio	$26.50	$78.25	195.28%	Hold
DAWN	Day One Biopharmaceuticals	$13.31	$38.80	191.51%	Buy
APLS	Apellis Pharmaceuticals	$26.27	$74.50	183.59%	Buy
NUVB	Nuvation Bio	$2.63	$6.75	156.65%	Buy
ARWR	Arrowhead Pharmaceuticals	$18.57	$45.38	144.37%	Buy
TERN	Terns Pharmaceuticals	$6.17	$14.25	130.96%	Buy
NXTC	NextCure	$1.31	$3.00	129.01%	Buy
ANNX	Annexon	$6.12	$14.00	128.76%	Buy
ASMB	Assembly Biosciences	$16.14	$35.50	119.95%	Buy
ACHL	Achilles Therapeutics	$1.05	$2.00	90.48%	Buy
WVE	Wave Life Sciences	$13.67	$22.14	61.96%	Buy
BPMC	Blueprint Medicines	$88.69	$109.71	23.70%	Buy
ALNY	Alnylam Pharmaceuticals	$235.56	$254.21	7.92%	Buy
PRQR	ProQR Therapeutics	$3.82	$3.63	-4.97%	Buy

PRQR Forecast FAQ

Is ProQR Therapeutics a good buy?

Yes, according to 5 Wall Street analysts, ProQR Therapeutics (PRQR) is considered a 'Buy'. The rating consensus is based on 1 'Strong Buy' and 3 'Buy' recommendations, accounting for 80.00% of PRQR's total ratings.

What is PRQR's price target?

ProQR Therapeutics (PRQR) average price target is $3.63 with a range of $2 to $5, implying a -4.97% from its last price of $3.82. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will ProQR Therapeutics stock go up soon?

According to Wall Street analysts' prediction for PRQR stock, the company can go down by -4.97% (from the last price of $3.82 to the average price target of $3.63), up by 30.89% based on the highest stock price target, and down by -47.64% based on the lowest stock price target.

Can ProQR Therapeutics stock reach $6?

PRQR's average twelve months analyst stock price target of $3.63 does not support the claim that ProQR Therapeutics can reach $6 in the near future.

What are ProQR Therapeutics's analysts' financial forecasts?

ProQR Therapeutics's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $30.05M (high $31.59M, low $28.5M), average EBITDA is $-30.807M (high $-27.068M, low $-34.545M), average net income is $-38.85M (high $-27.222M, low $-50.478M), average SG&A $165.9M (high $174.41M, low $157.38M), and average EPS is $-0.418 (high $-0.3, low $-0.537). PRQR's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $30.54M (high $32.57M, low $28.5M), average EBITDA is $-18.321M (high $-17.099M, low $-19.543M), average net income is $-18.858M (high $-17.223M, low $-20.494M), average SG&A $168.6M (high $179.84M, low $157.35M), and average EPS is $-0.231 (high $-0.211, low $-0.251).

Did the PRQR's actual financial results beat the analysts' financial forecasts?

Based on ProQR Therapeutics's last annual report (Dec 2022), the company's revenue was $4.04M, beating the average analysts forecast of $3.46M by 16.67%. Apple's EBITDA was $-59.384M, beating the average prediction of $-28.355M by 109.43%. The company's net income was $-64.891M, beating the average estimation of $-61.776M by 5.04%. Apple's SG&A was $18.65M, missing the average forecast of $19.06M by -2.17%. Lastly, the company's EPS was $-0.91, beating the average prediction of $-0.847 by 7.50%. In terms of the last quarterly report (Mar 2023), ProQR Therapeutics's revenue was $655K, missing the average analysts' forecast of $1.31M by -50.03%. The company's EBITDA was $-9.248M, missing the average prediction of $-15.171M by -39.04%. ProQR Therapeutics's net income was $-7.991M, missing the average estimation of $-14.487M by -44.84%. The company's SG&A was $4.03M, missing the average forecast of $7.24M by -44.37%. Lastly, the company's EPS was $-0.0988, missing the average prediction of $-0.117 by -15.56%